Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., AUG. 07, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT OR THE COMPANY), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025.

RAPT THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF SCOTT BRAUNSTEIN, M.D., AND ASHLEY DOMBKOWSKI, PH.D., TO ITS BOARD OF DIRECTORS. DR. BRAUNSTEIN WAS APPOINTED AS A MEMBER OF THE AUDIT COMMITTEE OF THE BOARD AND DR. DOMBKOWSKI WAS APPOINTED AS A MEMBER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF THE BOARD. THE COMPANY'S LEAD PRODUCT CANDIDATE RPT904, IS A NOVEL, HALF-LIFE EXTENDED MONOCLONAL ANTIBODY DESIGNED TO BIND FREE HUMAN IMMUNOGLOBIN E (IGE), A KEY DRIVER OF SEVERAL ALLERGIC DISEASES. RPT904 IS CURRENTLY COMPLETING PHASE 2 TRIALS IN CHRONIC SPONTANEOUS URTICARIA AND ASTHMA, AND RAPT PLANS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR FOOD ALLERGY LATER THIS YEAR.

RAPT THERAPEUTICS NAMES TWO INDUSTRY VETERANS TO ITS BOARD OF DIRECTORS

SOUTH SAN FRANCISCO, CALIF., JUNE 13, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (THE COMPANY), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT A 1-FOR-8 REVERSE STOCK SPLIT OF ITS OUTSTANDING SHARES OF COMMON STOCK WILL BE EFFECTIVE AT 11:59 PM EASTERN TIME JUNE 16, 2025.

RAPT THERAPEUTICS ANNOUNCES EFFECTIVE DATE FOR 1-FOR-8 REVERSE STOCK SPLIT

SOUTH SAN FRANCISCO, CALIF., JUNE 04, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE RAPT MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN JUNE:

RAPT THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., MAY 08, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT OR THE COMPANY), A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

RAPT THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., APRIL 15, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE, IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF JESSICA SAVAGE, M.D.

RAPT THERAPEUTICS DEEPENS EXPERTISE IN ALLERGIC DISEASES WITH APPOINTMENT OFJESSICA SAVAGE, M.D., M.H.S., AS VICE PRESIDENT, CLINICAL DEVELOPMENT

SOUTH SAN FRANCISCO, CALIF., MARCH 07, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE, IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE RAPT MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN MARCH:

SOUTH SAN FRANCISCO, CALIF., MARCH 06, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT) (RAPT OR THE COMPANY) IS A CLINICAL-STAGE IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS LIVING WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024.

RAPT THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., JAN. 09, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE, IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT BRIAN WONG, M.D., PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT A COMPANY OVERVIEW AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON THURSDAY, JANUARY 16, 2025 AT 9:00 A.M. PACIFIC TIME.

RAPT THERAPEUTICS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

SOUTH SAN FRANCISCO, CALIF., JAN. 06, 2025 (GLOBE NEWSWIRE) -- RAPT THERAPEUTICS, INC. (NASDAQ: RAPT), A CLINICAL-STAGE, IMMUNOLOGY-BASED BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING, DEVELOPING AND COMMERCIALIZING NOVEL THERAPIES FOR PATIENTS WITH INFLAMMATORY AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF LORI LYONS-WILLIAMS AS CHAIR OF ITS BOARD OF DIRECTORS, SUCCEEDING WILLIAM RIEFLIN, WHO STEPPED DOWN FROM THE BOARD EFFECTIVE JANUARY 3, 2025. MR. RIEFLIN WILL REMAIN AS A CONSULTANT FOR THE COMPANY.

RAPT Therapeutics, Inc.

RAPT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RAPT Therapeutics, Inc.

RAPT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RAPT